ReviewNature reviews. Neurology2016
CAP--advancing the evaluation of preclinical Alzheimer disease treatments.
Review in Nature reviews. Neurology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 57 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
57 citing papers in PubMed, 90 citations in OpenAlex.
- Trial
- The Value of Pre-Screening in the Alzheimer's Prevention Initiative (API) Autosomal Dominant Alzheimer's Disease Trial.The journal of prevention of Alzheimer's disease · 2018Trial
- Old worms, new tricks: dynamical instability explains late-life rejuvenation inbioRxiv : the preprint server for biology · 2026Article
- Operant House: A versatile open-source platform for automated operant conditioning testing of mice in home cages.PloS one · 2026Article
- A public resource of baseline data from the Alzheimer's Prevention Initiative Autosomal-Dominant Alzheimer's Disease Trial.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2023Article
- Plasma βAlzheimer's research & therapy · 2023Article
- Preclinical Alzheimer's dementia: a useful concept or another dead end?European journal of ageing · 2022Review
- Testing the amyloid cascade hypothesis: Prevention trials in autosomal dominant Alzheimer disease.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2022Article
- Planning for Prevention of Parkinson Disease: Now Is the Time.Neurology · 2022Article
- Article
- Prevalence Estimates of Amyloid Abnormality Across the Alzheimer Disease Clinical Spectrum.JAMA neurology · 2022Article
- GRK5 Deficiency Causes Mild Cognitive Impairment due to Alzheimer's Disease.Journal of Alzheimer's disease : JAD · 2022Review
- ASIC-E4: Interplay of Beta-Amyloid, Synaptic Density and Neuroinflammation in Cognitively Normal Volunteers With Three Levels of Genetic Risk for Late-Onset Alzheimer's Disease - Study Protocol and Baseline Characteristics.Frontiers in neurology · 2022Article
- Resting-state functional magnetic resonance imaging in a randomized clinical trial for Alzheimer's disease.Neuroimage. Reports · 2021Article
- A Comprehensive Machine Learning Framework for the Exact Prediction of the Age of Onset in Familial and Sporadic Alzheimer's Disease.Diagnostics (Basel, Switzerland) · 2021Article
- Classification of Alzheimer's Disease Leveraging Multi-task Machine Learning Analysis of Speech and Eye-Movement Data.Frontiers in human neuroscience · 2021Article
- Associations between vascular risk factors and subsequent Alzheimer's disease in older adults.Alzheimer's research & therapy · 2020Article
- Baseline demographic, clinical, and cognitive characteristics of the Alzheimer's Prevention Initiative (API) Autosomal-Dominant Alzheimer's Disease Colombia Trial.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2020Article
- The Alzheimer's Prevention Initiative Composite Cognitive Test: a practical measure for tracking cognitive decline in preclinical Alzheimer's disease.Alzheimer's research & therapy · 2020Article
- New Insights into the Molecular Bases of Familial Alzheimer's Disease.Journal of personalized medicine · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 9 institutions in 2 countries.
Funding
Abstract
If we are to find treatments to postpone, reduce the risk of, or completely prevent the clinical onset of Alzheimer disease (AD), we need faster methods to evaluate promising preclinical AD treatments, new ways to work together in support of common goals, and a determination to expedite the initiation and performance of preclinical AD trials. In this article, we note some of the current challenges, opportunities and emerging strategies in preclinical AD treatment. We describe the Collaboration for Alzheimer's Prevention (CAP)-a convening, harmonizing and consensus-building initiative to help stakeholders advance AD prevention research with rigour, care and maximal impact-and we demonstrate the impact of CAP on the goals and design of new preclinical AD trials.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.